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Abstract
 
Transgenic Balb/c mice expressing the transforming rat HER-2/neu oncogene develop early
and multifocal mammary carcinomas. Within the first 5 months of life the tissue-specific ex-
pression of HER-2/neu causes a progression in all their 10 mammary glands from atypical hy-
perplasia to invasive carcinoma. It was previously observed that chronic administration of inter-
leukin (IL)-12 increased tumor latency, but every mouse eventually succumbed to multiple
carcinomas. A significant improvement in tumor prevention was sought by administering allo-
geneic mammary carcinoma cells expressing HER-2/neu combined with systemic IL-12. This
treatment reduced tumor incidence by 90% and more than doubled mouse lifetime. For the
maximum prevention p185
 
neu
 
 antigen must be expressed by allogeneic cells. IL-12 treatment
strongly increased the cell vaccine efficacy. The mammary glands of mice receiving the com-
bined treatment displayed a markedly reduced epithelial cell proliferation, angiogenesis, and
HER-2/neu expression, while the few hyperplastic foci were heavily infiltrated by granulo-
cytes, macrophages, and CD8
 
 
 
 lymphocytes. Specific anti–HER-2/neu antibodies were pro-
duced and a nonpolarized activation of CD4
 
 
 
 and CD8
 
 
 
 cells secreting IL-4 and interferon
(IFN)-
 
 
 
 were evident. A central role for IFN-
 
  
 
in the preventive effect was proven by the lack
of efficacy of vaccination in IFN-
 
 
 
 gene knockout HER-2/neu transgenic Balb/c mice. A
possible requirement for IFN-
 
 
 
 is related to its effect on antibody production, in particular on
IgG2a and IgG2b subclasses, that were not induced in IFN-
 
 
 
 knockout HER-2/neu mice. In
conclusion, our data show that an allogeneic HER-2/neu–expressing cell vaccine combined
with IL-12 systemic treatment can prevent the onset of genetically determined tumors.
Key words: IL-12 • allogeneic vaccine • HER-2/neu • mammary carcinoma • 
immunoprevention
 
Introduction
 
Immunological prevention of tumors is a concept based on
the ability of immunity to arrest tumor progression in
healthy individuals with a high risk of cancer. Successful re-
sults have been reported in mice treated with chemical car-
cinogen (1) and in transgenic mice that develop mammary
(2) or prostate (3) carcinomas by using IL-12 (1, 2), cellular
vaccines (4), DNA vaccines (5, 6), recombinant proteins
(7), and adoptive immunotherapy (3).
While these studies provide significant proofs of concept,
the protection afforded was markedly influenced by the
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model adopted. Balb/c female mice transgenic for the
transforming rat HER-2/neu oncogene (Balb-neuT mice)
display an early development of multifocal mammary carci-
nomas. In these mice, final tumor incidence was not af-
fected but only significantly delayed by IL-12 systemic
treatment, while a 50% reduction in tumor incidence was
observed in FVB mice transgenic for rat HER-2/neu pro-
tooncogene (FVB-neuN), which develop fewer tumors
with a longer latency period (2). Both cytokines and anti-
gen-specific vaccines were effective, albeit through mark-
edly different reaction mechanisms (1–7). It should be
noted that in HER-2/neu transgenic mice the existence of
immunological tolerance to HER-2/neu, similar to what is
observed in patients with neu-expressing breast cancer, has
been documented (6, 8).
This paper reports the efficacy of combined allogeneic
tumor cell vaccination and IL-12 treatment in the preven-
tion of mammary carcinomas in virgin Balb-neuT mice.
Within the first 5 mo of age the tissue-specific expression
of HER-2/neu causes a progression in all their ten mam-
mary glands from atypical hyperplasia to an invasive carci-
noma that closely resembles human neoplasia (9). The
combination of cell vaccines and cytokine treatment we
have chosen inhibited tumor onset in a model of rapid pro-
gression to malignant mammary carcinoma.
 
Materials and Methods
 
Mice.
 
Balb-neuT female mice (H-2
 
d
 
) overexpressing the
transforming activated rat HER-2/neu oncogene under control
of the mouse mammary tumor virus promoter (2) were bred un-
der specific pathogen-free conditions by Charles River Laborato-
ries. IFN-
 
 
 
 gene knockout Balb/c mice from Jackson Immu-
noResearch Laboratories were crossed with Balb-neuT, and
IFN-
 
 
 
 knockout Balb-neuT mice (IFN-
 
 
 
 
 
/
 
 
 
 Balb-neuT mice)
selected by PCR analysis. The total number of backcrosses of
Jackson IFN-
 
 
 
 knockout mice to Balb/c mice was 10. When
spleen cells from IFN-
 
 
 
 knockout Balb-neuT mice were used as
stimulator in mixed lymphocyte cultures, no significant activation
of proliferative response of Balb-neuT responder T lymphocytes
was ever found. Only individually tagged virgin females were
used in experiments described here and were treated according to
the European Community guidelines. Mammary glands were in-
spected weekly, and tumor masses measured with calipers in two
perpendicular diameters. Progressively growing masses of 
 
 
 
3 mm
in mean diameter were regarded as tumors. Growth was moni-
tored until all 10 mammary glands displayed a tumor or until a
tumor exceeded a mean diameter of 1.5 cm, at which time mice
were killed for humane reasons.
 
Cells.
 
TT12 and N202.1E cell clones were derived from two
independent mammary carcinomas of FVB-neuN no. 202 mice
(H-2
 
q
 
), transgenic for the rat 
 
neu
 
 protooncogene (10). TT12 cells
(referred to as Neu/H-2
 
q
 
) expressed high levels of p185
 
neu
 
;
N202.1E cells (referred to as Neu
 
neg
 
/H-2
 
q
 
) lacked p185
 
neu
 
 (11).
TUBO cell clone (referred to as Neu/H-2
 
d
 
) was derived from a
carcinoma of Balb-neuT mouse (12). Cells were cultured in Dul-
becco’s modified minimal essential medium supplemented with
20% FBS (Life Technologies) at 37
 
 
 
C in a humidified 5% CO
 
2
 
atmosphere. In some experiments cells were treated with 40 
 
 
 
g/
ml of mitomycin C (MitC; Sigma-Aldrich) to block cell prolifer-
ation. Surface expression of p185
 
neu
 
 and class I H-2
 
q
 
 molecules
was assessed by flow cytometry as described previously (11) using
monoclonal antibodies 7.16.4 (p185
 
neu
 
; Oncogene Research
Products), KH114 (H-2K
 
q
 
; BD PharMingen), 34-7-23S (H-2D
 
q
 
;
Cedarlane), and 28-14-8S (H-2D/L
 
q
 
; BD PharMingen).
 
Vaccination and IL-12 Treatment.
 
Starting at the sixth week of
age Balb-neuT mice received successive 3-wk courses of four
twice-weekly intraperitoneal vaccinations with 2 
 
  
 
10
 
6
 
 alloge-
neic Neu/H-2
 
q
 
 mammary carcinoma cells in 0.4 ml of PBS, fol-
lowed by five daily intraperitoneal administrations of recombinant
mouse IL-12 (provided by S. Wolf, Genetics Institute, Andover,
MA) in the third week. In the first course the five injections were
of 50 ng of IL-12 in 0.2 ml of PBS supplemented with 0.01%
mouse serum albumin (MSA; Sigma-Aldrich), the subsequent in-
jections were of 100 ng. After 1 wk of rest, the course was re-
peated until mice were killed or were 1 y old. Control Balb-neuT
mice received either mock vaccination or MSA administration.
Their tumor progression mirrored that of untreated mice.
 
Morphologic and Immunohistochemical Analysis.
 
Groups of three
mice were killed at the indicated times. Tissue samples were pro-
cessed as described previously (9) for histologic evaluation or for
immunohistochemistry. The following antibodies were used: an-
tidendritic cells (NLDC 145; Cedarlane); anti-CD4, anti-CD8a
(both from Sera-Lab, Crawley Down); anti–Mac-1 (anti-CD11b/
CD18), anti–Mac-3, and anti-Ia (all from Boehringer Mann-
heim); anti-PMN (clone RB6-8C5, provided by R.L. Coffman,
Dynax); antiasialo GM1 (Wako Chemicals); anti–endothelial cells
(mEC-13.324) and anti–
 
e
 
ndothelial leukocyte adhesion molecule
E-selectin 1 (E-selectin), both provided by A. Vecchi, Istituto M.
Negri, Milano, Italy; anti–intercellular adhesion molecule 1
(CD54), anti–vascular cell adhesion molecule 1 (BD PharMin-
gen), and anti–monocyte chemotactic protein 1 (BD PharMin-
gen); anti–macrophage inflammatory protein (MIP)-2 (Walter
Occhiena Srl); anti-RANTES; anti–IFN-
 
 
 
 inducible protein
(IP)
 
*
 
-10; antimonokine induced by IFN-
 
 
 
 (MIG; R&D Sys-
tems); anti–IL-1
 
 
 
 (Genzyme), anti–TNF-
 
 
 
 (ImmunoKontact),
anti–IFN-
 
 
 
 (provided by S. Landolfo, University of Turin), and
anti-inducible nitric oxide synthase (Transduction Laboratories); anti–
vascular endothelial cell growth factor, anti–basic fibroblast growth
factor (Santa Cruz Biotechnology, Inc.), anti-p185
 
neu
 
 (C-18;
Santa Cruz Biotechnology, Inc.), and anti–proliferating cell nu-
clear antigen (PCNA; Ylem). Quantitative studies of immunohis-
tochemically stained sections were performed independently by
three pathologists in a blind fashion. From mice with multiple tu-
mors, one sample per tumor growth area and 10 randomly chosen
fields in each sample were evaluated for each point determination.
Positive cells were counted under a high-power (original magnifi-
cation: 
 
 
 
630) microscope field (0.114 mm
 
2
 
 per field).
 
IFN-
 
 
 
 and IL-4 Production from Spleen Cells.
 
Spleens were
collected from treated and control mice, and single cell suspen-
sions were prepared, washed in PBS, and resuspended in RPMI
1640 supplemented with 10% FBS. CD4
 
 
 
- and CD8
 
 
 
-enriched
T cells were positively selected by paramagnetic beads conjugated
with anti-CD4 and anti-CD8a monoclonal antibody, respectively
(Miltenyi Biotec). Unseparated, CD4
 
 
 
 and CD8
 
 
 
 cells (5
 
   
 
10
 
5
 
cells per milliliter) were then restimulated with MitC-treated tar-
get cells (5
 
   
 
10
 
4
 
 cells per milliliter) for 6 d at 37
 
 
 
C in RPMI
 
*
 
Abbreviations used in this paper:
 
 IP, IFN-
 
 
 
–inducible protein; MIG,
monokine induced by IFN-
 
 
 
; MIP, macrophage inflammatory protein;
MitC, mitomycin C; MMP, matrix metalloproteinase; MSA, mouse se-
rum albumin; PCNA, proliferating cell nuclear antigen; TEB, terminal
ductal end bud. 
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1640 with 10% FBS containing 10 U/ml recombinant mouse IL-2
(Peprotech). Supernatants were assayed for IFN-
 
 
 
 and IL-4 pro-
duction by ELISA assays from Endogen.
 
Antibody Response.
 
Sera collected from tumor-free mice at 13
wk of age were analyzed by flow cytometry, Western blot analy-
sis, and complement-mediated cytotoxicity as described previ-
ously (11) using various p185
 
neu
 
-positive and -negative cells. Ig
subclasses analysis was carried out by an indirect immunofluores-
cence procedure. Secondary fluorescein-conjugated monoclonal
antibodies directed against Ig subclasses were as follows: anti–
mouse IgG1 clone A85-1; anti–mouse IgG2a clone R19-15;
anti–mouse IgG2b clone R12-3; anti–mouse IgG3 clone R40-
82; anti–mouse IgM clone R6-60.2; anti–mouse IgA clone C10-3;
and anti–mouse IgE clone R35-72. All of them were purchased
from BD PharMingen.
 
Expression of Angiogenic and Antiangiogenic Factors.
 
Neu/H-2
 
d
 
mammary carcinoma cells were cultured for 48 h in the presence
and absence of 100 U/ml of mouse IFN-
 
 
 
 (given by G.R. Adolf,
Ernst-Boehringer Institute, Wien, Austria). Total RNA was ex-
tracted, retrotranscribed, and semiquantitative reverse tran-
scriptase polymerase chain reaction was performed as described
previously (13) with the following primers: glyceraldehyde-3-
phosphate dehydrogenase (GAPDH), purchased from CLON-
TECH; matrix metalloproteinase (MMP-9; reference 14); MIG
(forward 5
 
 
 
-TCC GCT GTT CTT TTC CTT TTG G-3
 
 
 
, re-
verse 5
 
 
 
-TTG AAC GAC GAC GAC TTT GGG G-3
 
 
 
); IP-10
(forward 5
 
 
 
-CTC CCC ATC AGC ACC ATG AAC-3
 
 
 
, reverse
5
 
 
 
-GTG GCT TCT CTC CAG TTA AGG A-3
 
 
 
).
 
Results
 
Prevention of Mammary Carcinogenesis.
 
Vaccination with
allogeneic mammary carcinoma cells (Neu/H-2
 
q
 
) express-
ing high surface levels of both p185
 
neu
 
 and H-2
 
q
 
 class I
molecules (Fig. 1) followed by intraperitoneal administra-
tion of IL-12 was used to halt mammary carcinogenesis in
Balb-neuT mice. IL-12 was chosen because of its ability to
significantly delay tumor onset (1, 2). Beginning when the
mice were 6 wk old, they received Neu/H-2
 
q
 
 cells twice-
weekly in the first and second week, followed by five daily
administrations of IL-12 in the third week. After 1 wk of
rest this course was repeated until mice were killed or
reached the age of 1 y.
This combined treatment effectively inhibited the devel-
opment of mammary carcinomas (Fig. 2). All control mice
developed their first mammary tumor within 22 wk, when
all mice treated with Neu/H-2
 
q
 
 cells plus IL-12 were com-
pletely tumor free. Within 30 wk all control mice devel-
oped tumors in all 10 mammary glands. At 52 wk (end of
the study) 88% of mice treated with Neu/H-2
 
q
 
 cells plus
IL-12 were still completely tumor free; their lifetime was
more than doubled.
 
Weight of the Treatment Components.
 
IL-12 alone pro-
duced a significant delay in tumor latency and a significant
reduction in tumor multiplicity, but did not affect tumor
incidence (Fig. 2), in agreement with our previous find-
ings (2). Vaccination with Neu/H-2
 
q
 
 cells alone delayed
tumor onset, but did not result in tumor-free mice (Fig.
2), thus indicating that IL-12 markedly contributes to the
efficacy of the combined treatment. Vaccination with the
Neu
 
neg
 
/H-2
 
q
 
 cells alone was ineffective and its combina-
Figure 1. Cytofluorometric analysis of HER-2/neu and MHC class I
glycoprotein expression in Neu/H-2q cells. Open profiles represent cells
stained with secondary antibody alone; solid profiles represent cells incu-
bated with the indicated antibodies. In each panel, the ordinate represents
the number of cells. Data from an experiment representative of at least
three similar experiments are shown.
Figure 2. Inhibition of mammary carcinogenesis in Balb-neuT female
mice. Groups of 7–8 mice received the indicated treatments. Tumor-free
survival curve of mice treated with Neu/H-2q cells plus IL-12 is signifi-
cantly different from all other curves (P   0.005 at least by the Mantel-
Haenszel test); tumor-free survival curves of mice treated with IL-12 or
Neu/H-2q cells are significantly different (P   0.05 at least) from MSA
controls. Tumor multiplicity is calculated as the cumulative number of
incident tumors/total number of mice and is shown as mean   SEM. 
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tion with IL-12 resulted in a protection similar to that af-
forded by IL-12 alone (Fig. 2). Therefore, p185neu recog-
nition appears to play a central role in halting HER-2/neu
carcinogenesis.
As the block of cell proliferation by MitC may reduce
the immunogenicity of a vaccine (15), while vaccination
with replicating cells poses practical issues, the need for live
and replicating cells was also evaluated. The combination
of MitC-treated Neu/H-2q cells with IL-12 resulted in a
block of carcinogenesis and all mice were tumor free at 1 yr
(Fig. 3). Vaccination with MitC-treated cells allowed us to
evaluate also the efficacy of syngeneic Neu/H-2d cells,
which otherwise would be tumorigenic; no protection was
obtained with such cells alone, whereas the delay in tumor
occurrence induced by Neu/H-2d cells plus IL-12 was not
longer than that elicited by IL-12 alone (see Fig. 2 for
comparison). These data point to a requirement for both
allogeneic MHC molecules and p185neu recognition for an
effective protection.
Pathological Evolution of the Mammary Gland. By the
third week of age foci of atypical hyperplasia were evident
in the numerous side buds (9, 16) of control mice and sub-
sequently extended to all 10 mammary glands. Foci of car-
cinoma in situ first apparent around the fifteenth week (Fig.
4 A) evolved to invasive lobular carcinomas by the twenti-
eth. 10 wk later invasive lobular carcinomas were present
in all the glands.
Treatment with IL-12 alone slowed down this progres-
sion. The atypical foci grew much more slowly and the on-
set of in situ and invasive carcinomas was delayed by 5–6
wk. The lesions were invaded by reactive cells (Fig. 4 B),
whereas a similar infiltrate was barely visible in the controls.
At the fifteenth week of age the side buds and the terminal
ductal end buds (TEBs) of mice treated with Neu/H-2q
cells plus IL-12 were carpeted with a single layer of epithe-
lial cells and surrounded by reactive cells. The few small
hyperplastic foci were the scene of intense inflammation
(Fig. 4 C). After the fifth course (at 27 wk), the mammary
tissue was mainly composed of small ducts with few TEBs.
Remaining side buds and TEBs were slightly hyperplastic
and surrounded by reactive cells. These were sometimes
found inside the lobular structures among the epithelial
cells (Fig. 4 D–F).
In mice treated with Neu/H-2q cells plus IL-12, attenu-
ated inflammation was present at 35, 40, and 45 wk of age
after the eighth or tenth course. In very few mice only in-
vasive lobular carcinomas developing from hyperplastic foci
were microscopically detectable. Their lobules were less
compact than in the controls, while the neoplastic epithe-
lial cells were poorly coherent and frequently disaggre-
gated, and gave rise to fissures. The stroma inside and
around the tumor was more abundant and occupied by a
distinct inflammatory infiltrate. Reactive cells were numer-
ous in the stroma of both the hyperplastic and the tumor
lesions, and occasionally intermingled with the neoplastic
cells after crossing or damaging the basal membrane.
Immunohistochemical examination after the second
course (fifteenth week of age) revealed a reduction of hy-
perplastic foci and TEBs containing epithelial cells express-
ing p185neu. At 27 wk, the mammary tissue of mice treated
with Neu/H-2q cells plus IL-12 was only constituted by
small ducts lined by a single layer of epithelial cells without
or with a slight p185neu expression confined to the cyto-
plasm (Fig. 5 A, C, and E) associated with a poor positivity
to PCNA (Fig. 5 B, D, and F). By contrast, a marked cyto-
plasmic and membrane p185neu expression, similar to hy-
perplastic and neoplastic lesions from untreated and IL-12–
treated mice, was displayed by the few carcinomas detected
in mice treated with IL-12 and cell vaccine.
A conspicuous macrophage, neutrophil, and CD8  lym-
phocyte infiltrate was present in the hyperplastic foci and in
the tumor stroma of mice treated with Neu/H-2q cells plus
IL-12 (Table I). The number of dendritic and NK cells also
increased, though it was not higher than in mice treated
with IL-12 only. Recruitment of reactive cells was accom-
panied by overexpression of endothelial adhesion mole-
cules in the small vessels.
Significantly fewer blood vessels were found in mam-
mary glands of mice treated with Neu/H-2q cells plus IL-
12 and of those receiving IL-12 only than in the controls.
By contrast, proinflammatory cytokines and chemokines
were more evident in mice treated with Neu/H-2q cells
plus IL-12 than in mice receiving IL-12 only and were al-
most absent in mammary glands from untreated controls.
Figure 3. Inhibition of mammary carcinogenesis in Balb-neuT mice
with MitC-treated allogeneic Neu/H-2q cells plus IL-12. Groups of eight
mice received the indicated treatments. Tumor-free survival curves are
significantly different (P   0.0005 by the Mantel-Haenszel test). Tumor
multiplicity is calculated as the cumulative number of incident tumors/to-
tal number of mice and is shown as mean   SEM.1199 Nanni et al.
Cell-mediated Reactivity. At the fifteenth week of age,
after the second course, groups of 3–5 control and treated
mice were killed to evaluate spleen cell reactivity. Both to-
tal spleen cell yield and the absolute number of CD4  cells
were significantly higher in mice treated with Neu/H-2q
cells plus IL-12. However, CTL assays against HER-2/
neu-positive or -negative targets showed only  10% of
specific lysis of HER-2/neu-positive targets by spleen cells
from Balb-neuT mice vaccinated with Neu/H-2q cells plus
IL-12. These spleen cells did not display any protective ac-
tivity when they were admixed with a tumorigenic dose of
Neu/H-2d syngeneic mammary tumor cells in a Winn-
type neutralization assay in Balb-neuT mice (data not
shown). On the other hand, an increased spontaneous pro-
liferation was displayed in vitro by the CD4  lymphocyte
subpopulation. It was further increased in an antigen-spe-
cific manner by the addition of mitomycin-blocked synge-
neic Neu/H-2d cells. Moreover, total spleen cells and
CD8  lymphocytes of mice repeatedly treated with Neu/
H-2q cells plus IL-12 spontaneously released more IFN- 
than leukocytes from control or IL-12–treated mice (Fig.
6). Large amounts of IFN-  were released by total and
CD8  spleen cells after restimulation by Neu/H-2q cells.
IL-4 was secreted spontaneously or after restimulation by
both total spleen cells and CD4  lymphocytes (but not by
CD8  lymphocytes) from mice treated with Neu/H-2q
cells plus IL-12. This cytokine release pattern was triggered
by the recognition of both H-2q allogeneic MHC glyco-
proteins and p185neu since IFN-  and IL-4 were produced
not only in response to p185neu plus alloantigens (Neu/
H-2q) but also by the presentation of p185neu on syngeneic
cells (Neu/H-2d) as well as by alloantigens alone (Neuneg/
H-2q) (Table II).
Role of IFN- . In IFN-  knockout Balb-neuT mice
the combined administration of Neu/H-2q cells plus IL-12
was totally ineffective (Fig. 7). This fading of the protection
points to the crucial role of IFN-  in the prevention ob-
served. Along with its numerous immunomodulatory ac-
tivities, IFN-  may also directly modulate tumor cell phe-
notype and the in vivo behavior of tumor cells. Our results
suggest that induced IFN-  can affect the behavior of
Neu/H-2d cells by inhibiting their angiogenic phenotype
and the HER-2/neu–mediated signaling pathways leading
to the neoplastic behavior (11). In vitro, IFN-  inhibited
the proliferation of Neu/H-2d cells, downmodulated their
membrane expression of p185neu (which was even reduced
by 80% by the combination of IFN-  and TNF- ) and the
production of the proangiogenic protease MMP-9, while it
Figure 4. Morphologic and im-
munohistochemical analysis of mam-
mary glands. Histology shows that at
week 15 the mammary tissue of
control mice (A) contains numerous
foci of atypical hyperplasia with areas
of lobular carcinoma in situ; the hy-
perplastic and neoplastic epithelial
cells occupy and fill out all the duc-
tal-lobular structures. The hyper-
plastic foci found in mice receiving
IL-12 (B) or Neu/H-2q cells plus
IL-12 (C) are less numerous and
prosperous than in control mice and
surrounded by an evident reactive
infiltrate. At 27 wk in mice treated
with Neu/H-2q cells plus IL-12 the
few surviving foci of hyperplasia (D)
are surrounded by an evident infil-
trate composed of reactive cells that
sometimes are found within epithe-
lial cells after crossing or damaging
the basal membrane. Immunohis-
tochemistry reveals that granulocytes
(E) and CD8  lymphocytes (F) are
present not only in the stroma but
also inside the lobular structure after
crossing the damaged basal mem-
brane (arrowheads). A–C, original
magnification:   200; D, original
magnification:  400; E and F, origi-
nal magnification:  630.1200 Immunoprevention of Mammary Carcinoma
strongly upmodulated the production of antiangiogenic cy-
tokines such as IP-10 and MIG (Fig. 8).
Antibody Response. High-titer antibodies binding Neu/
H-2q cells were detected in sera from mice vaccinated with
allogeneic Neu/H-2q cells (Fig. 9 A). Staining of NeuNeg/
H-2q cells was much lower than Neu/H-2q cells (mean
fluorescence intensity 61   9 vs. 332   11), thus suggest-
ing that sera of H-2d mice vaccinated with Neu/H-2q plus
IL-12 contained p185neu-reactive antibodies along with al-
loreactive anti–H-2q antibodies. Neither untreated control
mice nor mice treated with IL-12 alone produced antibody
against Neu/H-2q cells (Fig. 9 A). To circumvent the issue
of alloreactivity we performed a Western blot analysis (Fig.
9 B), which showed that antibodies of mice vaccinated
with Neu/H-2q plus IL-12 specifically recognized p185neu
(Fig. 9 B). Only sera from mice receiving cell vaccines re-
sulted cytotoxic against syngeneic Neu/H-2d tumor cells,
whereas no lysis was observed against syngeneic p185neu-
negative H-2d lymphocytes (Fig. 9 C). The lysis was stron-
ger when Neu/H-2q cell vaccine was combined with IL-
12 administration.
A much lower antibody response was displayed by IFN- 
knockout Balb-neuT mice treated with Neu/H-2q cells
plus IL-12. Cytofluorometric analysis of serum binding to
Neu/H-2q cells showed a mean fluorescence activity of
124   44 for IFN-  knockout Balb-neuT mice versus
396   39 for Balb-neuT mice (P   0.01).
Analysis of Ig subclasses in sera from Balb-neuT trans-
genic mice treated with the cell vaccine or with the vaccine
plus IL-12 is shown in Fig. 10. The combined treatment
with Neu/H-2q cells plus IL-12 significantly (P   0.05) in-
creased the level of IgG1, IgG2a, and IgG2b. By contrast,
in IFN-  knockout BALB-neuT mice receiving the vac-
cine plus IL-12 the treatment failed to increase the level of
all Ig subclasses except IgG1.
Discussion
Combination of an allogeneic cell vaccine with systemic
IL-12 prevented the onset of mammary carcinoma in tu-
mor-prone Balb-neuT mice. Their lifespan was more than
doubled, while the quality of their life was not impaired.
The protection afforded was much more effective than those
previously obtained in the same mice with the exogenous
cytokine alone (2) or DNA vaccination (12). It was even
stronger than that elicited by cytokines (2), DNA, or protein
vaccines (5–7) in other lines of HER-2/neu transgenic mice
which develop fewer tumors with a longer latency.
Figure 5. Mammary tissue from
untreated 27-wk-old mice (A and
B), mice receiving IL-12 (C and D),
or Neu/H-2q cells plus IL-12 (E and
F). Immunohistochemistry with
anti-p185neu antibody reveals that all
the neoplastic cells express the
p185neu in the cytoplasm and on
their membrane (A). A similar
p185neu expression pattern is evident
in the mammary epithelial cells of
the carcinoma in situ present in the
IL-12–treated mouse (C). The cyto-
plasmic and membrane expression of
the p185neu is associated with a marked
positivity of PCNA (B and D). The
mammary glands of mice treated with
Neu/H-2q cells plus IL-12 are mainly
composed of ductules lined by a sin-
gle layer of epithelial cells without or
with a slight p185neu expression
mainly confined in the epithelial cell
cytoplasm (E); the epithelial prolifer-
ation rate was low as assessed by
PCNA positivity (F). A–F, original
magnification:  400.1201 Nanni et al.
The treatment combined different immunological stim-
uli, namely p185neu, allogeneic class I MHC glycoproteins,
and IL-12. Their separate evaluation showed that all were
required. Balb-neuT mice receiving allogeneic Neu/H-2q
cells or IL-12 alone displayed a slower carcinogenesis, but
all eventually succumbed to carcinoma. Only mice receiv-
ing the combination were protected from carcinoma for up
to 1 y.
To analyze the contribution of cell-bound determinants
we replaced Neu/H-2q cells in the vaccine either with
Neuneg/H-2q cells, a p185neu loss variant, or with Neu/
H-2d cells, expressing p185neu on a syngeneic background.
The various cell lines derive from independent transgenic
carcinomas (11, 12), therefore the possibility that other
factors may contribute to their different vaccine effect can-
not be ruled out. The markedly higher protection afforded
by IL-12 in combination with Neu/H-2q cells, as opposed
to the poor resistance of mice vaccinated with IL-12 and
Neuneg/H-2q cells, underlines the crucial importance of
p185neu recognition. Similarly, the weight of allogeneic
MHC signal was evident when the effective protection
from carcinogenesis of mice receiving IL-12 and alloge-
neic Neu/H-2q cells was compared with the scarce effi-
cacy of treatments with IL-12 and syngeneic Neu/H-2d
cells. Allorecognition may provide a favorable cytokine
microenvironment, but also induce a rapid destruction of
Table I. Reactive Cell Content, Expression of Endothelial Adhesion Molecules, and Production of Cytokines, Angiogenic Factors, and 
Mediators in Tumors Growing in Balb-neuT Mice
MSA IL-12
Neu/H-2q cells 
plus IL-12
Reactive cellsa  
Dendritic cells 1.4   0.7   11.0   3.2b  9.3    2.8b
Macrophages 3.1   1.3 4.2   1.8 22.1   4.2c
PMN 4.5   2.0 4.6   2.3 23.3   5.2c
CD8+ lymphocytes 1.3   0.9 6.7   2.4b 12.7   3.7c
CD4+ lymphocytes 0.0 1.3   0.4b 2.0   0.6
NK cells 5.1   1.9  14.6   3.3b 11.2   3.5b
Microvessel count 14.4   2.2 9.0   1.8b 6.1   1.7b
Endothelial adhesion moleculesd
ELAM-1 – – +
ICAM-1 + + ++
VCAM-1 – –  
Cytokines and
mediatorsd
IL-1  –+ + +
TNF-     +
IFN-  –   +
MCP-1 – + ++
MIP-2    +
RANTES – –  
IP-10 + ++ ++
MIG + ++ ++
iNOS – + +
Angiogenic factorsd
VEGF     
bFGF + + +
aCell counts performed in ten randomly chosen high-power fields per sample. Results are mean   SD of positive cell per field.
bSignificantly different (P   0.001) from corresponding values in MSA control mice.
cSignificantly different (P   0.001) from corresponding values in MSA control and IL-12–treated mice.
dThe expression of adhesion molecules, cytokines, mediators, and angiogenic factors was defined as absent (-), scarcely ( ), moderately (+), and
strongly (++) present on cryostat sections decorated with the antibody.
bFGF, basic fibroblast growth factor; ELAM, endothelial leukocyte adhesion molecule E-selectin; ICAM, intercellular adhesion molecule; iNOS,
inducible nitric oxide synthase; MCP, monocyte chemotactic protein; VCAM, vascular cell adhesion molecule; VEGF, vascular endothelial cell
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the vaccine and facilitate the cross-presentation of p185neu
by host APCs (17).
Tumor prevention appeared to rest on the activation of
multiple immune mechanisms. The dissection of their in
vivo role was made difficult by the complexity of the reac-
tion elicited and the duration of treatments, however dis-
Figure 6. Release of cytokines by spleen cells restimulated or not in
vitro with Neu/H-2q cells. Spleen cells from untreated control mice
(white bar); from mice treated with IL-12 (gray bar); from mice treated
with Neu/H-2q cells (cross-hatched bar); and from mice treated with
Neu/H-2q cells plus IL-12 (black bar). Asterisks denote a significant dif-
ference (P   0.05 at least by Student’s t test) with untreated controls.
Mean   SEM of groups of 3–5 Balb-neuT mice.
Table II. In Vitro Production of Cytokines in Spleen Cells from 
Control and Vaccinated Balb-neuT mice after Restimulation with 
HER-2/neu-positive (Neu/H-2q) and -negative (Neuneg/H-2q) 
Allogeneic Cells or with HER-2/neu-positive Syngeneic
Cells (Neu/H-2d)
Released cytokine (ng/ml)
Vaccinated micea In vitro stimulation IFN-  IL-4
MSA None 0.12   0.07 0.00   0.00
Neu/H-2q 0.27   0.07 0.00   0.00
Neuneg/H-2q 0.40   0.23 0.00   0.00
Neu/H-2d 0.35   0.11 0.00   0.00
Neu/H-2q plus
IL-12 None 0.65   0.12 0.04   0.03
Neu/H-2q  3.37   0.95b 0.18   0.11
Neuneg/H-2q 2.86   0.64b 0.10   0.05
Neu/H-2d 1.81   0.32 0.11   0.00
aMice received two courses of vaccination.
bP   0.05 versus no restimulation (Student’s t test).
Figure 7. Lack of inhibition of mammary carcinogenesis in IFN- 
knockout Balb-neuT female mice. Transgenic mice received the indi-
cated treatments. Tumor multiplicity was calculated as the cumulative
number of incident tumors/total number of mice and is shown as
mean   SEM. Groups of 7–8 mice.
Figure 8. mRNA expression of angiogenic and antiangiogenic mole-
cules determined by reverse transcriptase PCR in Neu/H-2d mammary
carcinoma cells treated in vitro with IFN- . GAPDH, 20 cycles; MIG, 35
cycles; IP-10, 28 cycles; MMP-9, 28 cycles. Densitometric analysis was
performed and values reported under each band.1203 Nanni et al.
tinct immune responses were conspicuously present or ab-
sent in association with protection from tumor onset.
IL-12 alone significantly delays tumor progression
through its effects on cell-mediated immunity and angio-
genesis (18, 19). Tumors arising in Balb-neuT mice receiv-
ing IL-12 alone were infiltrated by dendritic cells, NK cells,
and CD8  lymphocytes. The local release of IFN-  in-
duced the expression of tertiary antiangiogenic mediators
such as IP-10 and MIG, and the microvessel density was
decreased. Similar findings have been obtained in other ex-
perimental models where IL-12 was employed for cancer
prevention (1, 2).
A stronger inflammatory response was evident in mice
receiving IL-12 and Neu/H-2q allogeneic cells. Local pro-
duction of MIP-2 and the expression of endothelial adhe-
sion molecules correlated with the recruitment of granu-
locytes which may damage tumor vessels and mediate
antibody-dependent cytotoxicity (20).
The combined treatment, but not IL-12 alone, elicited a
marked specific humoral immune response. Anti-p185neu
antibodies in the sera of treated mice may impair carcino-
genesis by inducing a functional block of p185neu receptor
function, downregulating its expression on the cell mem-
brane (21), and impeding its ability to form the homo or
heterodimers that spontaneously transduce proliferative sig-
nals to the cells (21, 22). The reduced number of p185neu-
positive cells, the intracytoplasmic confinement of p185neu,
and the diminished nuclear positivity to anti-PCNA mono-
clonal antibody in the mammary glands of mice treated
with Neu/H-2q cells plus IL-12 after the second course
point to a direct inhibitory activity by anti-p185neu anti-
body. The mammary glands of treated mice displayed
fewer and fewer side buds after each course. This is a criti-
cal issue in tumor prevention since progression leading to
the formation of invasive lobular carcinomas originates
from side buds proliferating cells (PCNA-positive) that
highly express p185neu (9, 16).
Activation of CD4  and CD8  cells by the combined
treatment was associated with cytokine release within the
mammary gland and in the spleen. Moreover, infiltrating
lymphocytes were present in the stroma surrounding neo-
plastic cells and penetrated the basal membrane to interact
with p185neu-positive neoplastic epithelial cells. This type
of tumor infiltration by lymphocytes was not observed in
Balb-neuT receiving IL-12 alone (2, 23) or Neu/H-2q cells
alone. In human carcinomas and melanoma, the presence
Figure 9. Antibody production by Balb-neuT mice. (A) Cytofluoro-
metric analysis of serum binding to Neu/H-2q cells. Each bar represents
the mean   SEM of sera (diluted 1:65) from three mice at the fifteenth
week of age bled after the second course of the indicated treatment. (B)
Neu/H-2q and Neuneg/H-2q cell extracts were immunoprecipitated by
sera from three mice treated with Neu/H-2q cells plus IL-12, PBS as neg-
ative control, and anti–rat p185neu monoclonal antibody 7.16.4 as positive
control (Neu mAb). Western blot analysis was performed using the an-
tineu polyclonal antibody C18. (C) Complement dependent cytotoxicity
against syngeneic Neu/H-2d cells and Balb-neuT lymphocytes, which do
not express p185neu (H-2d). The percentage of viable lymphocytes was
determined after a 30-min incubation with sera of mice bled after the sec-
ond course of treatment (diluted 1:10) followed by a 30-min incubation
with rabbit low-tox complement (diluted 1:10). Results are expressed as
100   % viable lymphocytes.
Figure 10. Subclasses of antibodies induced in Balb-neuT mice and in
IFN-  knockout Balb-neuT mice. Cytofluorometric analysis of serum
binding to Neu/H-2q cells with secondary anti–mouse isotype antibodies
is reported. Each bar represents the mean   SEM of sera (diluted 1:65)
from three mice at the fifteenth week of age bled after the second course
of the indicated treatment.1204 Immunoprevention of Mammary Carcinoma
of a reactive infiltrate intermingled with tumor cells, as op-
posed to the presence of leukocytes at the periphery of tu-
mor nests, often correlates with a more favorable prognosis
(24, 25).
In vitro no evidence of a major involvement of specific
CTL activity was found. Even though we cannot rule out
the possibility that CTL activity could contribute to the
preventive effect, data reported here show that in vitro cy-
totoxicity and Winn-type tumor neutralization assay were
not predictive of treatment efficacy. The absence of a mea-
surable CTL activity in lymphoid organs does not exclude
direct killing of HER-2/neu positive mammary cells at the
tissue level, but on the whole, it is unclear if vaccination
elicited T cells against HER-2/neu.
A major contribution of T cells, whether alloreactive or
recognizing HER-2/neu, was the copious production of
IFN- . The high IFN-  secretion by CD8  T cells from
mice receiving Neu/H-2q allogeneic cells plus IL-12 and
the loss of efficacy of this combined treatment in IFN- 
knockout Balb-neuT mice point to a central role of IFN- 
in the inhibition of carcinogenesis. Along with its numer-
ous activities, IFN-  directly modulates tumor cell pheno-
type and immunogenicity (26, 27). It is also the crucial
downstream mediator elicited by IL-12 (20) that induces
the expression of tertiary antiangiogenic mediators such as
IP-10 and MIG, and decreases the density of tumor mi-
crovessels (19). Our in vitro data (28) suggest that IL-12–
induced IFN-  modulates the behavior of Neu/H-2d cells
by inhibiting their angiogenic phenotype and the HER-2/
neu–mediated signaling leading to the neoplastic behavior
(11). IFN-  is also required for the complete activation of
effector T cells (29) and is crucial for the induction of
C-fixing IgG2a and IgG2b subclasses (30, 31).
In principle IFN-  might also favor tumor growth
through the downmodulation of tumor antigens (32),
however, this effect is probably irrelevant in HER-2/neu
carcinogenesis, because antigen p185neu expression is re-
quired for tumor growth (11), and the major consequence
of its downmodulation would be the loss of tumorigenic-
ity, rather than the enhancement of tumor growth resulting
from reduced tumor recognition by T cells. Other contra-
dictory effects of IFN-  in vivo, such as the enhancement
of metastatic spread (33), are exerted only on late stages of
tumor progression, thus do not play a role in the early steps
of mammary carcinogenesis which were prevented by the
combined treatment used here.
In summary the lack of efficacy of the combined treat-
ment in IFN- –deficient HER-2/neu transgenic mice
demonstrated that IFN-  is an essential component of the
immune response leading to mammary carcinoma preven-
tion. The breeding of Balb-neuT mice selectively deficient
for other immune functions will allow to better appraise
the weight of immune responses that were either strongly
induced by the combined treatment (e.g., humoral immu-
nity), or of uncertain value in determining the protective
effect (e.g., CTL activity).
In conclusion each component of the combined treat-
ment played a role, and a complete protection was ob-
tained when all components were included to induce a
wide spectrum of immune responses. Their concerted ac-
tion stopped a devastating cancer-prone condition affecting
all the ten mammary glands, and more than doubled the
lifespan of Balb-neuT mice. This impressive result suggests
that a similar approach might prevent tumors in persons
with a high risk of cancer.
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